Therefore, HDAC inhibitors emerge as a promising therapeutic option for individuals with breast cancer who are resistant to aromatase inhibitors due to the interplay between HDAC activity and glycolysis within tumor cells. This evidence concerns the gene CYP19A1 and breast carcinoma.